Skip to main content
Top
Published in: Critical Care 1/2011

Open Access 01-02-2011 | Poster presentation

Safety of drotrecogin alfa (activated) treatment in patients with severe sepsis on renal replacement therapy without additional anticoagulation

Authors: L Mirea, I Luca Vasiliu, R Ungureanu, A Balanescu, I Grintescu

Published in: Critical Care | Special Issue 1/2011

Login to get access

Excerpt

Patients with sepsis-induced acute renal failure on continuous renal replacement therapy (CRRT), who receive heparin, may be at higher risk of bleeding when drotrecogin alfa activated (DAA) is administered in addition to standard anticoagulation, especially surgical patients. There are some previous observations that no additional anticoagulation is necessary during simultaneous DAA infusion and CRRT. The aim of this study was to evaluate the safety of CRRT during DAA infusion without additional anticoagulant therapy. …
Metadata
Title
Safety of drotrecogin alfa (activated) treatment in patients with severe sepsis on renal replacement therapy without additional anticoagulation
Authors
L Mirea
I Luca Vasiliu
R Ungureanu
A Balanescu
I Grintescu
Publication date
01-02-2011
Publisher
BioMed Central
Published in
Critical Care / Issue Special Issue 1/2011
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc9544

Other articles of this Special Issue 1/2011

Critical Care 1/2011 Go to the issue